Reliable structure verification of candidate molecules is at the very core of any successful chemical discovery or development program. NMR provides unprecedented levels of information for unraveling the actual structure of compounds, and is an essential tool for chemists to confirm that they made what they intended to make. Read on to learn about ACD/Labs' efforts in the area of structure verification.
In pharma, drug substances (and the resulting formulated drug products) must conform to a variety of quality specifications in order to be approved for use by healthcare practitioners and patients. While most of us who have worked in pharma know the various regulatory statutes and advisory guidance (and can quote them chapter and verse!), my belief is that there is a challenge in the practical and efficient implementation of quality practices that support conformance. When considering the increasing ‘fracturing’ of supply chains that support demand for drug substances in both clinical and healthcare systems worldwide, this challenge only continues to grow.
There is widespread agreement that going digital will help us manage data better, make us more productive, more innovative and ultimately enable us to make smarter decisions—all the way from the bench to the boardroom. Yet, we remain relatively early in the transition from paper to paperless lab, despite the need for organizations to become more innovative and more competitive.
En route to SLAS 2016 in San Diego to talk about ‘Tackling Obstacles to Analytical Knowledge Externalization’ I was struck by the congruity of the breathtaking road I was taking with the topic planned for the Informatics–Data Wrangling session. National Geographic noted the road as “An exhilarating driving experience…In places, the road has narrow shoulders and sharp drop-offs, so stay alert”. The Informatics landscapes of modern science-based organizations also offer remarkable challenges to navigate.
Over the course of the last four months, we have been working with Scientific Computing to publish a series of articles on a subject that we feel very passionately about (and work very close with) at ACD/Labs – the externalization of scientific research and development (read the summary here). Essentially, we used this opportunity to address some key trends specific to this topic from various perspectives in the industry. Now that the series is complete, I wanted to give you an overview of the four articles to paint a broader picture of what we, and some of our customers and partners, are seeing today.